RVX.TO - Resverlogix Corp.

Toronto - Toronto Delayed Price. Currency in CAD
3.64
+0.03 (+0.83%)
At close: 3:52PM EDT
Stock chart is not supported by your current browser
Previous Close3.61
Open3.65
Bid3.57 x 0
Ask3.65 x 0
Day's Range3.60 - 3.67
52 Week Range1.11 - 4.31
Volume57,025
Avg. Volume124,192
Market Cap683.705M
Beta0.79
PE Ratio (TTM)N/A
EPS (TTM)-0.60
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.55
  • GlobeNewswire7 days ago

    Resverlogix Announces Voting Results from the 2018 Annual and Special Meeting of Shareholders

    CALGARY, Alberta, Sept. 12, 2018-- Resverlogix Corp. today held its Annual and Special Meeting of Shareholders in Calgary, Alberta. A total of 126,864,830 shares were represented in person or by proxy. ...

  • GlobeNewswire15 days ago

    Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018

    As a follow up to its July 17, 2018 news release, Resverlogix Corp. (“Resverlogix” or the “Company”) (RVX:TSX) announced today that it has presented at the first Clinical Trials in Alzheimer’s Disease (CTAD) Asia conference in Shanghai, China, this past weekend. Dr. Jeffrey Cummings, Founding Director of the Cleveland Clinic Lou Ruvo Brain Health Center, Las Vegas, Nevada, delivered a keynote presentation on the design and baseline characteristics of a pre-specified substudy of cognition in elderly patients in the Company’s ongoing Phase 3 BETonMACE clinical trial.

  • GlobeNewswire20 days ago

    Resverlogix Announces $26 Million Private Placement

    Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) announced today it has closed a private placement of approximately 10.4 million equity units at a price of $2.50 per unit for gross proceeds of approximately $26 million (US$20 million), based on an agreed discount to the 5-day volume weighted average price of the Company’s shares between July 30 and August 3, 2018. Each unit will be comprised of one common share and one-half (1/2) of a common share purchase warrant. Each full warrant will be exercisable at a price of $3.00 per share for a period of three years from the closing of the private placement.

  • Baystreet28 days ago

    Stocks in play: Resverlogix Corp.

    Announced it is supporting a satellite symposium on Saturday, August 25, at the European Society of ...

  • GlobeNewswire28 days ago

    Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018 in Munich

    Key Opinion Leaders gather to discuss: LDL-c: Done Deal, Next Epigenetics? Ewelina Kulikowski of Resverlogix to present data on the effect of apabetalone on vascular inflammation. CALGARY, Alberta, Aug. ...

  • ACCESSWIRElast month

    Today's Research Reports on Resverlogix, IMV, BELLUS Health and Hamilton Thorne

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • GlobeNewswirelast month

    Resverlogix Announces Seventh Positive Recommendation From The Data Safety Monitoring Board For Phase 3 Study of Apabetalone

    Resverlogix Corp. (“Resverlogix” or the "Company") (RVX.TO) today announced  that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 BETonMACE trial in high-risk cardiovascular disease (CVD) patients has completed a seventh planned safety review and recommended that the study should continue as planned without any modifications. The DSMB reviewed available study data and noted that no safety or efficacy concerns were identified, and will conduct additional periodic reviews. Resverlogix, the clinical steering committee, and all investigators remain blinded to the trial data.

  • GlobeNewswire2 months ago

    Resverlogix Intends to Pursue U.S. Listing

    Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) announced today that it intends to pursue a listing of its common shares in the United States. Accordingly, if necessary in order to comply with stock exchange minimum share price requirements and in connection with any future equity financing associated therewith, the Company intends to request shareholder approval for a consolidation of the Company’s common shares at an annual and special meeting of shareholders of the Company (the “Meeting”) to be held on September 12, 2018.

  • GlobeNewswire2 months ago

    Resverlogix Announces Upcoming Presentations at Clinical Trials in Alzheimer’s Disease (CTAD) Asia and Alzheimer’s Association International Conference (AAIC)

    Resverlogix Corp. (“Resverlogix” or the “Company”) (RVX.TO) announced today that it has been awarded two presentations at the Clinical Trials in Alzheimer’s Disease (CTAD) Asia conference in Shanghai, China. Design and Baseline Data of the Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial” which will highlight the design and baseline characteristics of a prespecified substudy of cognition in elderly patients in the Company’s ongoing phase 3 BETonMACE clinical trial.

  • ACCESSWIRE2 months ago

    Toronto Exchanges Stock Review BELLUS Health Helius Medical Technologies Resverlogix and Crescita Therapeutics

    LONDON, UK / ACCESSWIRE / July 9, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics. The TSX Venture Exchange shaved off 1.81 points, or 0.24%, to finish at 740.10. Today's stocks of interest consist of: BELLUS Health Inc. (TSX: BLU), Helius Medical Technologies Inc. (TSX: HSM), Resverlogix Corporation (TSX: RVX), and Crescita Therapeutics Inc. (TSX: CTX).

  • GlobeNewswire2 months ago

    Hemostemix Formalizes World-Class Scientific Advisory Board

    CALGARY, Alberta, July 05, 2018-- Hemostemix Inc. is pleased to announce the formalization of its Scientific Advisory Board. Members of the SAB are all leaders in their fields of expertise, which span ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Medicure, Hamilton Thorne, Resverlogix and Aphria

    NEW YORK, NY / ACCESSWIRE / July 5, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • Baystreet3 months ago

    Stocks in play: Resverlogix Corp.

    Is seeking a partnership with an existing stakeholder in the ongoing fight against HIV-1. The most ...

  • ACCESSWIRE3 months ago

    Today's Free Reports BELLUS Health Helius Medical Technologies Resverlogix and Crescita Therapeutics

    LONDON, UK / ACCESSWIRE / June 7, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics. The TSX Venture Exchange gained 7.25 points, or 0.94%, to finish at 775.10. Today's stocks of interest consist of: BELLUS Health Inc. (TSX: BLU), Helius Medical Technologies Inc. (TSX: HSM), Resverlogix Corporation (TSX: RVX), and Crescita Therapeutics Inc. (TSX: CTX).

  • ACCESSWIRE3 months ago

    Today's Research Reports on Resverlogix, Aphria, IMV and Oncolytics Biotech

    NEW YORK, NY / ACCESSWIRE / June 5, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • ACCESSWIRE5 months ago

    Canadian Exchanges Stock Scanner BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics

    LONDON, UK / ACCESSWIRE / May 04, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics. The TSX Venture Exchange shaved off 0.86 points, or 0.11%, to finish at 771.25. Today's stocks of interest consist of: BELLUS Health Inc. (TSX: BLU), Helius Medical Technologies Inc. (TSX: HSM), Resverlogix Corporation (TSX: RVX), and Crescita Therapeutics Inc. (TSX: CTX).